The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD. Here, we share a presentation by Steven Pavletic, Bethesda, US, discussing quality of life and symptoms in cGvHD.
Pavletic discussed the importance of the assessment of quality of life using patient-reported outcome measures (PROMs) in both clinical trials and clinical practice in cGvHD, outlining the frequently used PROMs in GvHD, including cGvHD-specific and dimension-specific measures. Pavletic highlighted that incorporation of PROMs into standard of care practice may ultimately lead to more tailored and effective clinical assessments.
This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
","author_name":"Scientific Education Support"}